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Background: Organ-preserving chemo-radiotherapy (CRT) is the standard of care for non-metastatic anal squamous
cell carcinoma (SCC). The optimal dosing schedules are yet to be determined. To improve local control rates, dose
escalation has been investigated but found to not increase efficacy at the expense of increased toxicity for an
unselected patient population.
Diffusion weighted imaging (DWI) and dynamic contrast enhanced (DCE) Magnetic Resonance Imaging (MRI)
performed during CRT have early data suggesting it to be an effective tool in predicting later tumour response for
SCC in related body sites.
By performing multi-parametric MRI (mpmMRI) incorporating standard morphological, DWI and DCE sequences,
we aim to determine whether the early changes in multi-parametric parameters during CRT can predict for later
response in anal SCC. This may create opportunities to investigate treatment adaptation, either intensification or
de-escalation, during CRT.
Methods/Design: This protocol describes a prospective non-interventional multi-centre single-arm clinical trial.
Twenty eligible patients with histologically confirmed non-metastatic anal SCC will receive standard definitive CRT
and undergo multi-parametric MRI’s at the following 4 time points; prior to treatment, during the second and fourth
weeks of treatment and 6-8 weeks following treatment.
Complete response will be defined by the absence of tumour persistence or recurrence as determined by clinical
examination at 6 months.
Images will be retrospectively analysed to determine the apparent diffusion coefficient and tumour perfusion
coefficients (Ktrans and Kep) at each time point. The Mann-Whitney-Wilcoxon Test will be utilised to compare the
change in these parameters for responder’s verses non-responders.
Discussion: If validated, mpmMRI, along with other risk factors, can be used to stratify patients and guide radiation
dosing in a prospective trial. Informed individualisation of treatment intensity should help us achieve our goals
of improved efficacy and reduced toxicity.
Trial registration: Australian New Zealand Clinical Trials Registry (ANZCTR): ACTRN12614001219673 (19/11/2014).
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Anal cancer
Prevalence and risk factors
Anal cancer (AC) is an uncommon malignancy, repre-
senting 2.2% of all gastrointestinal cancers. However, the
rate of AC is increasing [1]. This is likely due to the rising
prevalence of its strongest risk factors – Human Papilloma
Virus (HPV) and Human Immunodeficiency Virus (HIV)
[2-5]. The majority of anal squamous cell carcinomas
(SCCs) are associated with HPV infection and, in particu-
lar, the HPV-16 subtype [3,6].
Treatment
Pioneering data from the 1970s found that combined
chemo-radiotherapy (CRT) could achieve a complete
response in anal cancer [7]. Radical CRT has since
become the standard of care for non-metastatic AC
[8]. The long-standing combination of radiotherapy, 5-
Fluorouracil (5-FU) and Mitomycin-C (MMC) has been
validated in a series of large prospective randomised
controlled trials [9-13].
Multiparametric MRI
Diffusion Weighted MRI (DW-MRI)
DW-MRI is a functional MRI technique that measures
molecular diffusion resulting from normal Brownian mo-
tion of water protons within biological tissues [14]. Due to
architectural differences, biological tissues are variably re-
strictive of diffusion. In particular, the densely cellular and
disorganised architecture characteristic of cancer results
in low molecular diffusion and therefore low signal re-
sponse. Diffusion is measured quantitatively by the appar-
ent diffusion coefficient (ADC).
Dynamic Contrast Enhanced MRI (dCE-MRI)
DCE-MRI is performed by obtaining sequential MRI im-
ages acquired before, during and after intravenous injec-
tion of paramagnetic contrast [15]. DCE-MRI measures
the rate of contrast movement between the intravascular
and extra-cellular extravascular space. This rate reflects
tissue microvasculature permeability and perfusion. Can-
cer, with its abnormal neovasculature, tends to show char-
acteristic changes in the signal intensity compared with
normal tissues [16].
Rationale for the proposed study
Multiparametric MRI as a biomarker in anal cancer
Presently, CRT results in local failure rates of 14 to 37%,
even in patients with early stage disease [17-19]. Although
it is feasible to intensify the radiotherapy dose, this in-
creases toxicity, and a recent randomized trial has shown
that this dose escalation strategy is not beneficial for an
unselected patient population [10].Nigro et al. reported local control in 23 of 28 patients
who received an intermediate radiation dose of 30 Gy in
15 fractions combined with 1000 mg/m2 of 5-FU delivered
on days 1-5 and 29-33, and 15 mg/m2 of Mitomycin-C on
day 1 only [20]. More recently, Hu et al. [21] and Hatfield
et al. [22] found 30Gy sufficient to treat microscopic and
small volume (<2 cm) macroscopic disease.
This suggests there are some anal cancers that require
less than the current regimen of approximately 50-55 Gy,
and others that require more. Adaptive radiotherapy using
a biomarker would allow clinicians to tailor the treatment
dose to an individual patient’s tumour response. Such a
strategy could see decreased toxicity (perineal skin atro-
phy and fibrosis, sexual dysfunction, femoral neck frac-
tures and persistent gastrointestinal disturbance such as
sphincter dysfunction) and improved local control rates.
Diffusion-weighted MRI (DW-MRI) and dynamic contrast
enhanced MRI (dCE-MRI) performed during CRT have
early data suggesting it to be an effective tool in predicting
later tumour response for both cervical and head & neck
cancer [23,24]. As cervical and some head and neck SCCs
share a common aetiology with anal SCC via Human Papil-
loma Virus (HPV), there are grounds to hypothesize that
similar tumour response patterns may occur across these
various malignancies when treated with organ preserving
CRT. Application of this modality to anal cancer may allow
adaptation of radiotherapy dosing, both intensification and
de-escalation, to compensate for observed tumour biology.
Study hypothesis
DW-MRI and dCE-MRI performed during CRT for AC




This study is designed to be a single-arm, multicenter,
prospective, observational trial to investigate the value of




Correlation of mpmMRI parameters with tumour response.
Secondary study endpoint
Determine the feasibility of performing mpmMRI during
CRT for AC.
Study schematic
All patients will receive standardized CRT and have
mpmMRI performed at the four time points of pre-
treatment, weeks 2 and 4 of CRT, and then 6-8 weeks
following completion of CRT (Figure 1).
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Inclusion criteria
1. Patient capable of providing informed consent
2. Patient deemed suitable for protocol treatment as
assessed by Radiation and Medical Oncologists
3. Histological diagnosis of invasive primary squamous
cell carcinoma of the AC
4. TNM Stage: T2-4 N0-3 M0 based on the following
diagnostic work-up
a. History & physical examination including:
i. Digital Rectal Exam (DRE) stating primary
size and distance from anal verge
ii. Groin examination with documentation of
any lymphadenopathy
b. Anal biopsy
c. CT abdomen and pelvis
d. Whole Body PET/CT
5. Age ≥18Figure 1 Study Schematic. MpmMRI = Multi-parametric magnetic
resonance imaging, CRT = Chemo-radiotherapy, F/U = Follow-up.Exclusion criteria
1. ECOG performance status >2
2. Significant comorbidities that would interfere with
the completion of treatment
3. Renal insufficiency (Creatinine > 150)
4. Prior radiotherapy to the pelvis
5. Prior surgery for cancer of the anus that removed all
macroscopic cancer
6. Prior systemic chemotherapy for anal cancer
7. Evidence of distant metastases (M1) if this precludes
radical pelvic treatment
8. Women who are pregnant or lactating
9. Inability to have a MRI due to:a. Implanted magnetic metal e.g. intraocular metal
b. Pacemaker/Implantable defibrillator
c. Extreme claustrophobiaRadiation therapy
The radiation technique must be one of either:
 Intensity Modulated Radiation Therapy (IMRT)
 Volumetric Modulated Arc Therapy (VMAT)
 Tomotherapy
The treatment plan is at the discretion of the treating
Radiation Oncologist and should be determined by ana-
lysis of the volumetric dose, the Dose Volume Histograms,
planning target volume (PTV) and critical normal struc-
tures. An “inverse” planning method will be used with the
aim of delivering dose to the PTV while maximally sparing
the normal tissues.Target prescription dose
Dose and fractionation for radical treatment is guided
by the Australasian Gastrointestinal Trials Group
(AGITG) guidelines [25]. The target prescription dose
shall be determined as follows:
For T2N0 disease
 The primary tumour PTV will receive 50.4 Gy in 28
fractions at 1.8 Gy per fraction
 The uninvolved nodal PTVs will receive 42 Gy in 28
fractions at 1.5 Gy per fraction
For T3-4 N0 disease
 The primary tumour PTV will receive 54 Gy in 30
fractions at 1.8 Gy per fraction.
 The uninvolved nodal PTVs will receive 45 Gy in 30
fractions at 1.5 Gy per fraction.
For N1-3 disease:
 The primary tumour PTV will receive 54 Gy in 30
fractions at 1.8 Gy per fraction.
 For involved nodes ≤ 3 cm in maximum dimension,
the involved nodal PTV will receive 50.4 Gy in 30
fractions at 1.68 Gy per fraction.
 For involved nodes > 3 cm in maximum dimension,
the involved nodal PTV will receive 54 Gy in 30
fractions at 1.80 Gy per fraction.
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The following dose specifications are recommended:
 98% of the relevant PTV should receive >95% of the
prescription dose
 No more than 2% of the relevant PTV should
receive >107% of the prescription dose
Treatment schedule
Treatment will be delivered once daily on weekdays, 5 days
per week except on public holidays. Missed fractions will be
made up for at the end of treatment at the discretion of the
treating clinician. All PTVs will be treated simultaneously.
Treatment breaks will be avoided, if possible, or minimised.Treatment planning
Target volume definitions are as per ICRU Reports 50,
62 and 83. Treatment planning is as per the Australasian
Gastrointestinal Trials Group (AGITG) Contouring Atlas
and Planning Guidelines for Intensity-Modulated Radio-
therapy in Anal Cancer [25]. This will include elective
nodal irradiation of the mesorectum, presacral space,
ischiorectal fossa, inguinal, obturator, internal and external
iliac lymph nodes,
Gross tumour volumes (GTV) The gross disease is
determined by physical examination, CT, PETand/or MRI.
Clinical target volume (CTV) The primary CTV must
encompass:
1. GTV
2. Entire anal canal from the ano-rectal junction to the
anal verge
3. Internal and external anal sphincters
A further 10-20 mm isotropic margin should be added to
items (1), (2), and (3) above, to account for microscopic
disease, while respecting anatomical boundaries. For the in-
volved nodes or nodal regions, a 10-20 mm margin should
be used, respecting anatomical boundaries.
Planning target volume (PTV) An isotropic 10 mm ex-
pansion is recommended on CTVs to generate PTVs.
Daily image guidance is recommended, which may allow
CTV-PTV margin reduction to 5-7 mm.
Dose constraints
The following normal tissue dose constraints are recom-
mended. Where available, values are taken from the
QUANTEC papers. Where not available for that organ,
dose constraints are listed as per the RTOG 0529 closed
study protocol (Table 1).Chemotherapy
Concurrent chemotherapy will begin on the first day of
radiotherapy. The second course of chemotherapy will
commence on calendar day 29 [4,9].
5-Fluorouracil (5-FU)
5-FU shall be delivered at a dose of 800-1000 mg/m2/day
via the IV route for 96 hours continuously starting on day
1 and repeated on day 29. In the instance of an unplanned
treatment break, the second cycle of 5-FU shall be deliv-
ered on the 29th day of radiotherapy treatment.
Mitomycin-C
Mitomycin-C shall be delivered at a dose of 10 mg/m2
(without exceeding a maximal single dose of 20 mg) via
the IV route on day 1 +/- day 29, depending on local
practice.
Pathology
All biopsy tissues will be formalin fixed, paraffin embed-
ded and routine H&E stained. Immunohistochemical
p16 staining is to be performed for all tumours as recent
data suggests that p16 positivity correlates with HPV sta-
tus and is associated with reduced relapse rates and im-
proved overall survival [26].
Follow-up and surgery
At 6-8 weeks post CRT, the patient will have a mpmMRI
performed.
The follow-up schedule is at the discretion of the




○ If negative, reassess in 4 weeks
○ If positive and no evidence of distant disease,
consideration of abdominoperineal resection (APR)
is recommended
Persistent disease
 No biopsy, reassess in 4 weeks
 Patients with clinical suspicion of persistent disease
at 26 weeks should undergo a biopsy and
consideration of APR, if positive.
Complete clinical response
 No biopsy
 Continue to follow-up at the discretion of treating
clinician
Table 1 Recommended organ at risk dose constraints
ORGAN CONSTRAINTS: No More than
Small Bowel 195 cc above 45 Gy 1% of small bowel > 52 Gy
Femoral Head 50% above 30 Gy 35% above 40 Gy 5% above 44 Gy
Iliac Crests 50% above 30 Gy 35% above 40 Gy 5% above 50 Gy
External Genitalia 50% above 20 Gy 35% above 30 Gy 5% above 40 Gy
Bladder 50% above 55 Gy
Large Bowel 50% above 50 Gy
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Imaging schedule
MpmMRI consists of standard morphological MRI,
DW-MRI and dCE-MRI. Patients will undergo mpmMRI
at the following four time points:
 Prior to CRT
 During the second week of treatment (fraction days
6-10)
 During the fourth week of treatment (fraction days
16-20)
 At 6-8 weeks post treatment
Imaging process
MRI’s are performed on a 3 Tesla device. Patients are
scanned in the supine position. No rectal coil is used. All
patients should have a single IV bolus of Buscopan
(20 mg/ml) immediately prior to the first sequence.
Diffusion weighted imaging
 Performed at 4 b-values○ 0, 400, 800 and 1200Dynamic contrast enhanced imaging
 Contrast injection:○ Magnevist 0.2 ml/kg
○ Power Injector (2.5 ml/s)
○ 20 ml saline chase at same rate as injectionThe eGFR must be checked prior to the MRI to ensure
eligibility for full contrast injection. Half doses are not
permitted.
Imaging analysis
Standard morphological MRI (SM-MRI) All images
will be assessed independently by two radiologists to
determine primary and nodal tumour dimensions.
Where there is disagreement, a third will be asked to
mediate.
Diffusion weighted MRI (DW-MRI) A Region Of Inter-
est (ROI) will be placed over primary and involved nodalregions to calculate mean and median primary and nodal
ADC values
Dynamic contrast enhanced MRI (dCE-MRI)
 A ROI will be placed over the entire primary and
involved nodal regions to calculate mean and
median primary and nodal Ktrans and Kep values
and Relative Signal Intensity (RSI) (Figure 2)
Statistical considerations
Sample size determination
Assuming that 70% of patients are positive responders,
then sample sizes of 14 responders and 6 non-responders
will achieve between 70% and 80% power to show a differ-
ence in mean change (initial to final) in SM-MRI of be-
tween 1.2 and 1.4 standard deviations at the 0.05
significance level (alpha) using a two-sided Mann-
Whitney-Wilcoxon Test. Previous studies in other body
locations have shown a positive result with similar pa-
tient numbers. We anticipate recruitment to be
achieved within 24 months.
Definition of complete response
 No evidence of residual tumour at 26 weeks post
CRT
 No progression requiring APR prior to 26 weeks
Ethical considerations
This protocol along with the informed consent docu-
ment and patient information sheet has received ethics
approval from the Hunter New England Human Research
Ethics Committee (HREC). The protocol also has radi-
ation safety approval.
Study finances
This study has been funded by both the Hunter Transla-
tional Cancer Research Unit (HTCRU) and the Royal
Australian and New Zealand College of Radiologists
(RANZCR), each with a $20,000 competitive research
grant (Total = $40,000). Neither the HTCRU nor the
RANZCR have been involved in the writing of this
protocol or will have any influence on the analysis or
publication of the study.
Figure 2 Anal cancer. Morphological MRI (top left and top middle), apparent diffusion coefficient map (top right), dynamic contrast enhanced
parametric maps (bottom, from left to right): KTrans, Kep and Ve.
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There is no consensus on the optimal radiation dose for
the treatment of patients with AC. It is very likely that
small tumours are often over-treated and large tumours
sometimes under-treated. Although TNM staging is
highly prognostic for AC, there is still significant hetero-
geneity in outcomes within a particular stage. Improved
prognostication may be achieved with further information
such as HPV status and mpmMRI tumour response. If this
exploratory phase 2 study finds compelling evidence for
an imaging biomarker being independently predictive of
later tumour response, a subsequent study would aim
to validate this by intensifying radiotherapy dose for
tumours with unfavourable biology, and deescalating
radiotherapy dose for favorable tumours. If validated,
an imaging biomarker for response to CRT would
allow clinicians to adapt and personalise treatment,
which holds the potential for improved efficacy and
reduced toxicity.
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